522. Evaluation of Three COVID-19 Monoclonal Antibody Regimens in the Context of Rising B.1.526 Prevalence in New York City

BACKGROUND: Monoclonal antibodies were given emergency use authorization (EUA) by the Food and Drug Administration for the treatment of high-risk, outpatient COVID-19 infection. In New York City (NYC), the emergence and rapid growth of the B.1.526 variant of concern (VOC) possessing the E484K mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Hongkai, Guo, Yi, Cowman, Kelsie, Chen, Victor, Nori, Priya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644702/
http://dx.doi.org/10.1093/ofid/ofab466.721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644702/
http://dx.doi.org/10.1093/ofid/ofab466.721

Ejemplares similares